Genta, a biopharm company focused on the oncology market, today announced that it has added the first patient to a new randomized trial of tesetaxel as initial chemotherapy for women with advanced or recurrent breast cancer.
The company expects to enroll 220 patients for the 12-month, randomized phase 2b study, which will be conducted across 15 sites in the U.S. and Western Europe.
The participating women will not have previously received chemotherapy for metastatic or recurrent disease, though eligible patients who are HER2-negative may have received adjuvant chemotherapy and hormonal therapy.
The study will compare two oral chemotherapy agents; patients will be randomized to one of three treatment groups administered twice per day for 14 consecutive days. The primary endpoint of the trial is overall response rate; secondary endpoints include progression-free survival and safety.
In the previously conducted two phase 2a studies, tesetaxel was generally well-tolerated. In the first study, 13 of 34 patients (38 percent) achieved a major objective response, and 11 patients achieved stable disease, for a disease control rate of 70 percent. In the second trial, 20 of 44 patients (45 percent) achieved major objective responses with a disease-control rate of 82 percent.
“Our preliminary results suggest that tesetaxel may compare favorably with capecitabine across a number of parameters, including response, safety, convenience, and compliance,” Dr. Loretta M. Itri, Genta’s president and chief medical officer stated in the press release. “Genta has now completed two, non-randomized, phase 2a studies comprised of more than 80 patients. The Company has been engaged in extended discussions with regulatory authorities in the U.S. and EU regarding potential registration strategies for tesetaxel in breast cancer. We believe this new study will provide a firm basis for a phase 3 trial design as first-line chemotherapy in this patient population.”
For more information visit www.genta.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment